Navigation Links
Cleveland Clinic study shows vitamin E may decrease cancer risk in Cowden syndrome patients
Date:9/17/2012

Saturday, September 15, 2012, Cleveland: Cleveland Clinic researchers have discovered that vitamin E may prevent cancer in patients with an under-recognized genetic disorder.

Several genetic mutations are known to be present in Cowden Syndrome (CS) a disease that predisposes individuals to several types of cancers, including breast and thyroid cancers. One type of mutation in the succinate dehydrogenase (SDH) genes may be responsible for cancer development, according to research by Charis Eng, M.D., Ph.D., Hardis Chair and Director of the Genomic Medicine Institute and Director of its Center for Personalized Genetic Healthcare at Lerner Research Institute, published today in Clinical Cancer Research.

Dr. Eng discovered that mutations in SDH genes, responsible for energy production, result in an accumulation of reactive oxygen species (ROS). These changes damage the cells and make them resistant to apoptosis our bodies' natural method of weeding out cancerous cells.

However, when vitamin E was applied to the mutant cells, ROS accumulation decreased, as well as the accompanying cellular damage.

"These findings support the notion that vitamin E may be useful as an anti-cancer therapeutic adjunct or preventive agent, especially for CS patients harboring SDH mutations, and its protective properties should be further explored," said Dr. Eng.

CS predisposes individuals to several types of cancers an 85 percent lifetime risk of breast cancer, a 35 percent risk for epithelial thyroid cancer, and increased risk of other cancers as well. Approximately one in 200,000 people are affected by CS.


'/>"/>

Contact: Stephanie Jansky
janskys@ccf.org
216-636-5869
Cleveland Clinic
Source:Eurekalert

Page: 1

Related medicine news :

1. Cleveland Clinic selected to participate in National MDS Clinical Research Consortium
2. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
3. Cleveland Clinic Florida receives approval for transplant programs at Weston Facilities
4. Cleveland Clinic researchers investigating potential drug for treatment of Alzheimers disease
5. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
6. First targeted nanomedicine to enter human clinical studies
7. Clinical insight improves treatment with new lung cancer drug
8. Clinical news alert from the American Academy of Orthopaedic Surgeons
9. Mayo Clinic launches whole genome breast cancer study
10. Mayo Clinic offers newly approved treatment for acid reflux disease
11. NYU Langone experts present research, clinical advances at neurosurgeons meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. Manju R. ... for leading-edge care, whether or not they have a referral. Dr. Kejriwal offers ... iPlus™ laser, she targets bacteria and damaged tissue without affecting the surrounding tissue. ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that ... Denville, NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at their ... orthodontics can cause for some patients, which is why they offer the latest in ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants in ... on finding product improvements that could reduce the occurrence of unplanned extubations (UEs). ... help breathing or to provide medication. Sometimes, patient movement can cause unplanned extubations ...
(Date:6/20/2017)... ... 20, 2017 , ... In his newly appointed role as ... Ph.D., recently accepted the distinguished Sun Corridor Export Award for his company’s global ... and 16 other businesses from Pima, Pinal, and Maricopa counties in Arizona, and ...
(Date:6/20/2017)... ... June 20, 2017 , ... Total Security Integrated Systems, ... as the partner of choice by Amtrak to fulfill several projects in various ... and long-distance intercity service in the contiguous United States. Security Executives at the ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/30/2017)... 30, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... Healthcare Conference on Tuesday, June 13, 2017, in ... Hill-Rom,s president and chief executive officer, is scheduled to present ... webcast can be accessed at http://ir.hill-rom.com/events.cfm . A recorded ... live event through September 13, 2017. ...
Breaking Medicine Technology: